Laboratory Testing for Connective Tissue Disease Evaluation
Start with antinuclear antibody (ANA) testing by indirect immunofluorescence assay (IIFA) on HEp-2 cells at a screening dilution of 1:160, which serves as the gold standard first-line test for connective tissue disease screening. 1
Initial Screening Approach
The diagnostic algorithm begins with ANA-IIFA because it has >95% sensitivity for systemic lupus erythematosus (SLE) and detects antibodies in most other connective tissue diseases 1. However, recognize that ANA positivity alone is non-specific and occurs in healthy individuals, infections, malignancies, and other inflammatory conditions 2.
When ANA is Positive
Report both the titer (highest dilution showing reactivity) and the specific pattern, as these guide subsequent testing 1:
- Homogeneous pattern → Test anti-dsDNA antibodies (suggests SLE)
- Speckled pattern → Test anti-ENA panel (anti-Sm, anti-RNP, anti-Ro/SSA, anti-La/SSB)
- Nucleolar pattern → Test anti-Scl-70, anti-RNA polymerase III (suggests systemic sclerosis)
- Centromere pattern → Anti-centromere antibodies (suggests limited cutaneous systemic sclerosis/CREST)
Disease-Specific Reflex Testing
For Suspected SLE
- Anti-dsDNA antibodies using Farr assay or Crithidia luciliae immunofluorescence test (CLIFT) for highest specificity 1
- Report quantitatively for disease monitoring 1
- Consider anti-Sm, anti-ribosomal P if clinically indicated
For Suspected Sjögren Syndrome
- Anti-Ro/SSA and anti-La/SSB antibodies even if ANA is negative 2
- These can be present without positive ANA
For Suspected Rheumatoid Arthritis
- Rheumatoid factor (RF) - sensitive but non-specific 2
- Anti-cyclic citrullinated peptide (anti-CCP) antibodies - more specific and confirms diagnosis 2, 3
For Suspected Inflammatory Myopathies
- Anti-Jo-1 antibodies should be ordered based on clinical suspicion regardless of ANA result 1
- Consider full myositis panel if available
For Suspected Mixed Connective Tissue Disease
- Quantitative anti-RNP antibodies 1
Critical Caveats
Order anti-Ro/SSA antibodies for congenital heart block, neonatal lupus, or subacute cutaneous lupus even with negative ANA 1. This is a common pitfall—certain antibodies can be present without detectable ANA by standard methods.
Do not order "arthritis panels" indiscriminately 3. Testing should be driven by pretest probability based on clinical findings, not as shotgun screening.
Supplementary Tests
When appropriate based on clinical context:
- Inflammatory markers: ESR or CRP (CRP correlates better with disease activity in RA) 4
- Complement levels (C3, C4): Low in active SLE
- Complete blood count: Cytopenias suggest SLE or other CTDs
- Urinalysis: Proteinuria/hematuria in lupus nephritis
Laboratory Reporting Standards
The laboratory must specify 1:
- The exact method used (IIFA vs. ELISA vs. multiplex)
- For IIFA: Both titer and pattern using standardized terminology
- Quantitative or semi-quantitative results for anti-dsDNA and anti-ENA
- Each antibody result separately, including negatives
Use the same method consistently for serial monitoring 1, particularly for anti-dsDNA in SLE disease activity assessment.
Key Pitfall to Avoid
The most common error is ordering ANA by non-IIFA methods (ELISA, multiplex) which may miss certain antibodies and have lower sensitivity. IIFA on HEp-2 cells remains the reference standard 1. If your laboratory uses alternative methods, understand their limitations and consider IIFA confirmation for negative results with high clinical suspicion.